EnteroMedics (ETRM) : During the past 4 weeks, traders have been relatively bearish on EnteroMedics (ETRM), hence the stock is down -39.36% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -13.83% relative to the S&P 500. The 4-week change in the price of the stock is -36.71% and the stock has fallen -12.54% in the past 1 week. The stock has recorded a 20-day Moving Average of 22.49% and the 50-Day Moving Average is 47.11%.
EnteroMedics (NASDAQ:ETRM): The stock opened at $0.34 on Friday but the bulls could not build on the opening and the stock topped out at $0.34 for the day. The stock traded down to $0.20 during the day, due to lack of any buying support eventually closed down at $0.26 with a loss of -27.35% for the day. The stock had closed at $0.36 on the previous day. The total traded volume was 5,937,926 shares.
The company Insiders own 13.7% of EnteroMedics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 271.26% . Institutional Investors own 12.34% of EnteroMedics shares. During last six month period, the net percent change held by insiders has seen a change of 271.26%. In a related news, Delange Peter M., officer (SVP, Ops & Bus Dev) of Enteromedics Inc, executed a transaction worth $11,000 on June 3, 2016. A total of 20,000 shares were purchased at an average price of $0.55. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.